Dear Editor,

Accumulating evidence suggests that hypoxemic acute respiratory failure (ARF) is independently associated with poor outcomes in patients successfully resuscitated after out-of-hospital cardiac arrest (OHCA) \[[@CR1]\]. This finding opens new therapeutic perspectives, targeting lung injury, to improve the prognosis of OHCA patients. Experimentally, Cyclosporine A (CsA) has been shown to prevent systemic inflammation-induced ARF \[[@CR2], [@CR3]\]. To investigate the effect of CsA on ARF in the clinical setting, we conducted a post-hoc analysis of the prospective, multicenter, randomized CsA in OHCA resuscitation (CYRUS) trial (ClinicalTrials.gov identifier: NCT01595958).

The CYRUS trial failed to demonstrate a significant decrease in the sequential organ failure assessment (SOFA) score at 24 h after nonshockable OHCA in patients receiving a prehospital single injection of 2.5 mg/kg CsA \[[@CR4]\]. All the 129 patients alive at 24 h included in the intention-to-treat analysis (67 in the CsA group and 62 in the control group) were analyzed in the present post-hoc analysis (without correction for multiple comparison), in which the primary endpoint was the occurrence of ARF at 24 h, as defined by a SOFA respiratory sub-score \> 2. The CsA effect was adjusted for history of respiratory disease, respiratory cause of OHCA and for relevant variables with *p* \< 0.1 after univariate analysis.

Patient's and OHCA's characteristics were well matched between the two groups (Table [1](#Tab1){ref-type="table"}). At admission, both the median (interquartile) ratio of the arterial partial pressure of oxygen to the fractional inspired oxygen (PaO~2~/FiO~2~) and the percentage of patients with ARF did not significantly differ between the CsA and the control groups: 211 (133--319) versus 207 (131--318) mmHg and 34.3% versus 32.3%, respectively. At 24 h, ARF was significantly less frequent in the CsA group (29.8%) compared to the control group (54.8%) and median PaO~2~/FiO~2~ was 68 mmHg higher in the CsA group (Table [1](#Tab1){ref-type="table"}). Patients treated with CsA were also less likely to fulfill criteria for acute respiratory distress syndrome (Table [1](#Tab1){ref-type="table"}). Importantly, CsA was still independently associated with a lower risk for ARF after multivariate analysis (OR 0.33; 95%CI \[0.16--0.70\], *p * \< 0.01) (Supplementary Table 1). This result was confirmed in the per-protocol population of the CYRUS trial (i.e. 61 patients who actually received CsA and 68 patients who did not) by both univariate analysis (ARF in 33% versus 50% of patients, respectively, *p * \< 0.05) and multivariate analysis (OR 0.42; 95%CI \[0.20--0.88\], *p * = 0.02).Table 1OHCA-induced acute respiratory failureCyclosporine group (*n* = 67)Control group (*n* = 62)*p*-value*Patients* Age (years)62.1 (52.9--72.7)63.5 (53.8--72.3)0.651 Male42 (67.2)47 (75.8)0.332 History of respiratory disease10 (14.9)8 (12.9)0.741 History of cardiac disease36 (53.7)35 (56.4)0.756*OHCA* Arrest at place of residence40 (59.7)46 (74.2)0.119 Respiratory cause22 (32.8)22 (35.5)0.751 Cardiac cause33 (49.3)24 (38.7)0.228 Bystander cardiopulmonary resuscitation31 (46.3)26 (41.9)0.723 Duration of untreated cardiac arrest (min)8 (5--12)10 (4--14)0.340 Time from collapse to ROSC (min)35 (27--46)32 (24--41)0.358 Target temperature management51 (76)44 (71)0.550*Cardiovascular dysfunction at 24 h*  Mean arterial pressure (mmHg)75 (64--91)79 (63--89) \> 0.99  Heart rate (beats per min)95 (75--112)91 (75--105)0.464  Left ventricular ejection fraction (%)50 (30--65)55 (40--60)0.899  Vasoactive drugs43 (64.2)39 (62.9)0.880*Respiratory dysfunction at 24 h* Mechanical ventilation67 (100)62 (100)N/A Ventilator settings  FiO~2~ (%)40 (35--60)50 (40--70)0.230  PEEP (cmH~2~O)5 (4--6)5 (5--6)0.278  Tidal volume (mL/kg)6.6 (6.1--8.2)6.4 (5.8--7.9)0.593  Minute ventilation (L/min)10.6 (8.5--12.6)10.7 (7.8--12.8)0.749 Sedation/curarization42 (62.7)30 (48.4)0.102 Chest quadrants with infiltrates2 (1--3)2 (1--4)0.522 Arterial blood gases  pH7.32 (7.24--7.41)7.36 (7.29--7.43)0.116   PaCO~2~ (mmHg)36 (31--42)35 (32--41)0.914   PaO~2~ (mmHg)104 (82--135)91 (77--121)0.103   PaO~2~/FiO~2~ (mmHg)\*255 (180--337)187 (125--304)0.021  Lactate (mmol/L)2.8 (1.7--4.5)3.0 (1.9--5.1)0.603 Acute respiratory failure^†^20 (29.8)34 (54.8)0.019 Acute respiratory distress syndrome^‡^5 (7.4%)11 (17.7%)0.108Data are expressed as median (interquartile range) or number (%) and compared using Wilcoxon, chi-square or Fisher's exact tests, as appropriate*OHCA* out-of-hospital cardiac arrest, *ROSC* restoration of spontaneous circulation, *SOFA* sequential organ failure assessment score, *PEEP* positive end-expiratory pressure, *PaCO*~*2*~ arterial partial pressure of carbon dioxide, *PaO*~*2*~*/FiO*~*2*~ ratio of the arterial partial pressure of oxygen to the fractional inspired oxygen\*Imputed, if needed, using adjusted pulse saturation of oxygen (SpO~2~) to FiO~2~ ratio (n = 2 patients in the control group)^†^Defined as PaO~2~/FiO~2~ ratio \< 200 mmHg in mechanically ventilated patients^‡^Defined according to Berlin criteria

We report here the first clinical data suggesting that CsA might limit the severity of ARF at 24 h following OHCA. Even though this post-hoc analysis of the CYRUS trial does not provide mechanistic insight, our findings are in line with both experimental and clinical studies reporting potent protective effects of CsA against ischemia/reperfusion (I/R) injury \[[@CR1], [@CR2], [@CR3], [@CR5]\]. CsA may indeed limit I/R-induced cellular damages by inhibiting the cyclophilin D-dependent opening of the mitochondrial permeability transition pore and by preserving oxidative phosphorylation \[[@CR5]\]. In acute lung injury models, cytoprotection was also attributed to a decrease in circulating mitochondrial pro-inflammatory and pro-apoptotic factors \[[@CR2], [@CR3]\]. Studies are now needed to examine the longer-term effects of CsA on lung injury, which could not be done here due to high early mortality rate.

In conclusion, the present study identified CsA as a potential new therapeutic strategy to prevent cardiac arrest-induced ARF. This finding will need further confirmation.
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